CJC-1295 sem DAC
Also known as: Mod GRF 1-29, CJC-1295 no DAC
Molecular Identifiers
Molecular Formula
C152H252N44O42
CAS Number
446036-97-1
PubChem CID
56841945Molecular Weight
3367.9 Da
Overview
Short-acting version of CJC-1295 (also known as Mod GRF 1-29). Mimics natural GH pulses with a half-life of ~30 minutes. Best results when combined with GHRP peptides such as Ipamorelin or GHRP-2.
The DAC-free version of CJC-1295 — also called Mod GRF 1-29 — is valued precisely for the opposite profile of the DAC version: with a half-life of about 30 minutes, it generates acute GH pulses that mimic natural physiology and theoretically reduce the risk of pituitary desensitization. It is sought for body recomposition, recovery, deep sleep, and hormonal optimization.
It has no approval as a medicine by the FDA, EMA, or ANVISA. In Brazil it is prescribed by compounding pharmacies as off-label use, in 8 to 12-week cycles, with 2-3 subcutaneous applications daily (morning, post-workout, and before bed). It is almost always combined with a GHRP such as Ipamorelin or GHRP-2 for synergistic effect — GHRH analog + GHRP produce GH pulses far greater than either peptide alone. WADA prohibits GHRH and analogs in sport.
It was developed by ConjuChem as a modified GHRH(1-29) analog with substitutions that increase resistance to enzymatic degradation. The DAC-free version corresponds to the same base peptide without the linker that conjugates to albumin.
Among GHRH analogs, Mod GRF 1-29 occupies a middle ground: greater enzymatic stability than sermorelin (native GHRH 1-29), yet a much shorter half-life than CJC-1295 with DAC or tesamorelin. This short-pulse profile is what drives its classic pairing with GHRPs such as ipamorelin, GHRP-2, or hexarelin, and distinguishes it from the tonic oral elevation of MK-677.
YADAIFTQSYRKVLAQLSARKLLQDILSR Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg Half-life
~30 minutes
Administration Route
Subcutaneous
Category
GH Secretagogues
Mechanism of Action
- Modified analog of GHRH (1-29)
- Pulsatile stimulation of GH secretion
- Short half-life (~30 min) mimics natural physiology
- Synergism with GHRP peptides
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 100-200 mcg per injection |
| Frequency | 2-3 times daily |
| Timing | Morning, post-workout, and before bed |
| Duration | 8-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Facial flushing
- Headache
- Dizziness
- Tingling in extremities
Product Properties
| Purity | >99% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of CJC-1295 sem DAC found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per 2 mg vial
- Slowly inject the diluent along the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Room temperature or refrigerated (up to 24 months)
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on CJC-1295 sem DAC.
Related Peptides
CJC-1295 with DAC
1-2 mg per week · Once per week
GHRP-2
100-300 mcg per injection · 2-3 times per day
GHRP-6
100-300 mcg per injection · 2-3 times per day
Hexarelin
200-300 mcg per injection · 2-3 times per day
Ipamorelin
200-300 mcg per injection · 2-3 times daily
MK-677
10-25 mg per dose · Once daily